Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617201 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
A Phase 2 study of Substance Abuse, sponsored by Sharon Walsh.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00617201: Completed Phase 2 study of Substance Abuse, sponsored by Sharon Walsh.
NCT00617201 is a Phase 2 study of Substance Abuse that has completed, run by Sharon Walsh. The registered enrollment target is 50 participants, below the 5,259-participant average among 58 other Substance Abuse trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617201, a Phase 2 study of Substance Abuse, has completed, sponsored by Sharon Walsh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.
Primary Outcome
Total % urine samples negative for benzoylecgonine over the 12-week trial
Conditions Studied
Interventions
- DRUG placebo
- DRUG atomoxetine
Study Locations (1)
Kentucky
- Straus Research Building - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00617201 record still lists
NCT00617201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 5,259-participant average among 58 other Substance Abuse trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00617201 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00617201 about?
NCT00617201 is a clinical study titled "Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial". This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine ...
What is the current status of trial NCT00617201?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-07. Estimated completion is 2011-08.
What conditions does trial NCT00617201 study?
This clinical trial studies the following conditions: Substance Abuse.
What interventions are being tested in trial NCT00617201?
The interventions under investigation include: placebo (DRUG), atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00617201?
This trial is sponsored by Sharon Walsh, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00617201 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00617201's enrollment target sits among peer trials
50 50th of 58 higher than 9 of 58 other Substance Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes
COMPLETED · Phase 2
-
Evaluation of Treatments for Homeless Youths
COMPLETED · Phase 2
-
Substance Treatment and HIV Testing and Referral System
COMPLETED · Phase 2
-
Study of Medical Treatment for Methamphetamine Addiction
COMPLETED · Phase 2
-
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
COMPLETED · Phase 2
-
Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia